Navigation Links
Pharmacyclics Reports Recent Developments and Financial Results for Fiscal Second Quarter 2011
Date:2/4/2011

of the patients receiving PCI-27483 experienced a thromboembolic event. We are currently in the Phase II portion of the study enrolling patients who receive either gemcitabine alone or gemcitabine plus PCI-27483 (dose at 1.2 mg/kg twice daily). We anticipate completion of enrollment in the Phase II portion during calendar year 2011.Financial Results for Second Quarter Fiscal 2011 The non-GAAP (Generally Accepted Accounting Principles) net loss reported for the fiscal quarter ended December 31, 2010 was $6.1 million, or $0.10 per share. This compares with a non-GAAP net loss of $1.4 million, or $0.03 per share, for the fiscal quarter ended December 31, 2009. Reconciliation between GAAP and non-GAAP results is provided at the end of this press release.

The GAAP net loss for the fiscal quarter ended December 31, 2010 was $7.5 million, or $0.13 per share. This compares with a GAAP net loss of $0.2 million, or $0.00 per share for the fiscal quarter ended December 31, 2009.

Total revenue was $2.8 million for the fiscal quarter ended December 31, 2010.   Upon the signing of a drug supply agreement with Les Laboratoires Servier ("Servier") in the quarter ended December 31, 2009, the company began recognizing revenue from its collaboration agreement with Servier, which was entered into in April 2009.  Total revenue for the fiscal quarter ended December 31, 2009 was $4.7 million, of which $1.2 million represents the pro rata portion of revenue attributable to the period from April 2009 (i.e., the signing of the collaboration agreement) to June 30, 2009.

As of December 31, 2010, the company had cash, cash equivalents and marketable securities totaling $61.6 million. This compares with $74.1 million in cash, cash equivalents and marketable securities as of June 30, 2010, our prior fiscal year end. We received the third scheduled payment of $1.0 million from our Collaboration and License Agreement with Les Laboratoires Servier in November 2010 a
'/>"/>

SOURCE Pharmacyclics, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9

Related biology technology :

1. Pharmacyclics Announces Date of Fourth Quarter and Fiscal Year End 2009 Conference Call
2. Pharmacyclics to Present and Webcast at Upcoming Life Sciences Investor Conferences
3. Pharmacyclics, Inc. Rights Offering Oversubscribed
4. Pharmacyclics Announces Subscription Price for Rights Offering
5. Pharmacyclics to Present at the 8th Annual Needham and Company Life Sciences Conference
6. Pharmacyclics Files Registration Statement for Rights Offering
7. Pharmacyclics Reports Second Quarter Fiscal 2009 Financial Results
8. Pharmacyclics Announces Appointment of New Management Team and Board Director to Accelerate Its Future Growth
9. Pharmacyclics Secures $5.0 Million in Debt Financing
10. Pharmacyclics Reports First Quarter Fiscal 2009 Financial Results
11. Pharmacyclics Reports Fourth Quarter and Fiscal 2008 Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/22/2014)... MA (PRWEB) November 21, 2014 ... key investors will gather on December 3rd at ... Biotech Conferences series. GeneticRx will take place at ... Medical School and will discuss the present and ... therapy, exon skipping, and gene editing—as well as ...
(Date:11/22/2014)... November 21, 2014 On November 17th ... the 2014 Emerging Medical Technologies Summit in San Francisco ... Widely regarded among Silicon Valley investors and technology ... innovation, the win also positions Briteseed to move ... competition in 2015 and compete with other elite innovation ...
(Date:11/22/2014)... 21, 2014  The element of surprise has been ... they strike without warning. Until now, epidemiologists had nothing ... viral outbreak, resulting in suboptimal responses to both the ... Photo - http://photos.prnewswire.com/prnh/20141121/160242 ... removed because virus gene structural changes have been found ...
(Date:11/21/2014)... Nov. 21, 2014   TRU-D SmartUVC LLC and ... superbug-killing UVC automated disinfection robot, TRU-D SmartUVC, at FIS 2014 ... Nov. 23 to 26 at Stand 23. The ... United Kingdom,s largest infection-related event of its ... to one of the leading events of its type throughout ...
Breaking Biology Technology:Pioneering Academics and Key Industry Leaders to Discuss Rare Diseases and the Emergence of New Genetic Medicines at Genetic Rx on December 3rd 2Insight Product Development Accelerator Member Wins MedTech Innovator Award Competition 2Insight Product Development Accelerator Member Wins MedTech Innovator Award Competition 3Viruses' Advantage of Surprise is Lost 2TRU-D SmartUVC to Showcase Superbug-Killing Robot at FIS 2014 2TRU-D SmartUVC to Showcase Superbug-Killing Robot at FIS 2014 3
... screens with siRNA libraries, Ambion scientists identified , ... screen results. , ... Reduce siRNA concentration Use , ... Correct for cell number Note cell type , ...
... RNA later protects cellular RNA , ... Whether you are in the lab, in the OR, ... can use this aqueous, non-toxic Tissue Collection:RNA , ... -20C. , Characterization ...
... Kit , , ... protocols optimized to minimize endogenous RNase activity , ... histological and fluorescent stains , Designed for use , ... , Compatible with Arcturus LCM Systems , ...
Cached Biology Technology:Recommendations for Successful siRNA Library Screens 2Recommendations for Successful siRNA Library Screens 3Recommendations for Successful siRNA Library Screens 4Recommendations for Successful siRNA Library Screens 5Recommendations for Successful siRNA Library Screens 6Recommendations for Successful siRNA Library Screens 7Recommendations for Successful siRNA Library Screens 8Preserve Samples for RNA Expression Microarrays RNAlater Around the World 2Preserve Samples for RNA Expression Microarrays RNAlater Around the World 3Preserve Samples for RNA Expression Microarrays RNAlater Around the World 4Preserve Samples for RNA Expression Microarrays RNAlater Around the World 5Protect RNA and Improve Target Cell Identification 2Protect RNA and Improve Target Cell Identification 3Protect RNA and Improve Target Cell Identification 4Protect RNA and Improve Target Cell Identification 5Protect RNA and Improve Target Cell Identification 6
(Date:11/6/2014)... groundbreaking paper from a team of Florida State University ... plants could adapt to and survive environmental swings such ... the latest issue of the journal The Plant ... of DNA and proteins) is organized in a cell ... genes are turned on and others are turned off. ...
(Date:11/6/2014)... November 6, 2014 - Insilico Medicine, Inc, a ... and age related diseases announced a research collaboration ... cancer, Champions Oncology, Inc (OTC: CSBR). , "There ... personalized medicine, but Champions Oncology,s TumorGraft technology is ... the chemotherapy regimen experimentally generating vast amounts of ...
(Date:11/5/2014)... great diversity in their ability to identify scents and ... in their perceptual evaluation of odors, with women outperforming ... , Sex differences in olfactory detection may play a ... to one,s perception of smell, which is naturally linked ... has been suggested to be cognitive or emotional, rather ...
Breaking Biology News(10 mins):Maize analysis yields whole new world of genetic science 2Insilico Medicine, Inc announces research collaboration with Champions Oncology, Inc 2The female nose always knows: Do women have more olfactory neurons? 2
... people usually don,t die from a heart attack. But the ... succumb to congestive heart failure, the most common cause of ... hope for achieving what the body can,t do: mending broken ... built a scaffold that supports the growth and integration of ...
... -- A microscopic gene may play a gigantic role when ... to one Kansas State University research team. The team ... Disintegrin and Metalloprotease family, or ADAM family, and its role ... is a good guy or a bad guy in breast ...
... against cancerous tumors, radiation therapy often harms healthy tissue as ... of Tel Aviv University,s Department of Biomedical Engineering is developing ... and minimal damage to surrounding tissue. His innovative ... uses heat to kill the tumor cells but leaves ...
Cached Biology News:A strategy to fix a broken heart 2A strategy to fix a broken heart 3K-State research team investigates mutated gene's role in breast cancer 2A 'magnetic' solution to identify and kill tumors 2
Goat Anti-Horse IgG(T) Antibody, Unconjugated...
Identify and characterize Phosphoinositide (PI(3,4,5)P3) binding...
Mouse polyclonal antibody to MCFD2 - multiple coagulation factor deficiency 2...
Rabbit polyclonal to ErbB 2 (phospho Y1248) ( Abpromise for all tested applications). entrezGeneID: 2064 SwissProtID: P04626...
Biology Products: